Novo Nordisk reported DKK146.38B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
ANI Pharmaceuticals USD 607.23M 3.26M Sep/2026
Aurora Cannabis CAD 22.68M 1.18M Jun/2026
Bausch Health Companies USD 20.72B 64M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Canopy Growth CAD 277.33M 1.38M Jun/2026
Corcept Therapeutics USD 8.99M 430K Sep/2026
Drreddys Laboratories INR 72.29B 5.05B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Novo Nordisk DKK 146.38B 27.66B Mar/2026
Pacira USD 293.59M 69.53M Sep/2026
Perrigo USD 3.29B 337.7M Jun/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 2.07B 1.02B Jun/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
Zoetis USD 9.24B 0 Jun/2026